구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KQ-2003 CAR T-cells (KQ-2003 CAR T-cells) Novatim Immune Therapeutics (Zheji…·Multiple Myeloma 3 trials |
|---|---|
Overview Program | KQ-2003 CAR T-cells |
Overview Company | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. |
Overview Modality | CGT |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.. Under compassionate use, CAR T cells have elicited durable remissions in patients with refractory systemic sclerosis (SSc). Here, we report on the safety, efficacy, and correlative data of the first SSc subject treated with a fully human CD19-CART cell therapy (resecabtage… |
Toxicology CRS | Reported |
Clinical Safety signal | Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.. Under compassionate use, CAR T cells have elicited durable remissions in patients with refractory systemic sclerosis (SSc). Here, we report on the safety, efficacy, and correlative data of the first SSc subject treated with a fully human CD19-CART cell therapy (resecabtage… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KQ-2003 CAR T-cells (KQ-2003 CAR T-cells) Novatim Immune Therapeutics (Zheji…·Multiple Myeloma 3 trials |
|---|---|
Overview Program | KQ-2003 CAR T-cells |
Overview Company | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. |
Overview Modality | CGT |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.. Under compassionate use, CAR T cells have elicited durable remissions in patients with refractory systemic sclerosis (SSc). Here, we report on the safety, efficacy, and correlative data of the first SSc subject treated with a fully human CD19-CART cell therapy (resecabtage… |
Toxicology CRS | Reported |
Clinical Safety signal | Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.. Under compassionate use, CAR T cells have elicited durable remissions in patients with refractory systemic sclerosis (SSc). Here, we report on the safety, efficacy, and correlative data of the first SSc subject treated with a fully human CD19-CART cell therapy (resecabtage… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교